A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors

NCT01562275 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Ipatasertib
DRUG: Cobimetinib

Sponsor

Genentech, Inc.